Visceral fat reduction and increase of intracellular fluid in weight loss participants on antihypertension medication
Visceral fat reduction and increase of intracellular fluid in weight loss participants on antihypertension medication
复制标题
DOI：
10.1097/xce.0000000000000222
复制
发表时间：
2021-03-01
影响因子：
2.3
通讯作者：
Barnes, Jessica W.
中科院分区：
文献类型：
--
作者：
Dembrowski, Gerald C.;Barnes, Jessica W.
目的高血压和肥胖之间复杂的生理相互作用导致并维持了高发病率和死亡率。随着高血压和肥胖的患病率达到流行病的比例，我们询问抗高血压药物是否会影响参与者的能力，以达到与其他参与者相同的身体成分改善水平，这些参与者参与了一项全面的减肥计划，重点是减少内脏脂肪组织。专家监督的减肥计划，包括类似于6周的专有的、营养全面的、非常低热量的饮食（VLCD），然后是类似于3周的结构化过渡，恢复正常的饮食摄入。总体而言，33%的受试者报告至少服用一种处方降压药。（+/-抗高血压药物）在体重减轻的标准测量和与炎症和高血压直接相关的终点方面实现了临床相关和统计学显著的改善。非手术的基于VLC的减肥和代谢健康计划能够在身体组成和生理终点方面产生临床上有意义的改善，包括与高血压、心血管疾病和炎症相关的终点，并且对于服用处方抗高血压药的成年人和未服用处方抗高血压药的参与者同样有效。版权所有（c）2020威科医疗集团All rights reserved.
Objectives Complex physiological interactions between hypertension and obesity contribute to and perpetuate a heightened morbidity and mortality. With the prevalence of both hypertension and obesity reaching epidemic proportions, we asked whether antihypertensive medications affect the ability of participants to achieve the same level of body composition improvements as other participants in a comprehensive weight loss program focused on reduction of visceral adipose tissue.Methods Data was analyzed from 2200 subjects completing a commercially available, expert supervised weight loss program including similar to 6 weeks of a proprietary, nutritionally complete, very low-calorie diet (VLCD) followed by a similar to 3-week structured transition back to a normal dietary intake. Overall, 33% of the subjects reported taking at least one prescription antihypertensive medication.Results Our data show participants in both groups (+/- antihypertensive drugs) achieved clinically relevant and statistically significant improvements in standard measures of weight loss and endpoints directly related to inflammation and hypertension.Conclusion A nonpharmacologic, nonsurgical VLCD-based weight loss and metabolic health program is capable of producing clinically meaningful improvements in body composition and physiological endpoints, including those linked to hypertension, cardiovascular disease and inflammation, and is as equally effective for adults taking prescription antihypertensives as it is for those participants who are not. Copyright (c) 2020 Wolters Kluwer Health, Inc. All rights reserved.